Search

Your search keyword '"Lash, Robert"' showing total 49 results
Start Over Author "Lash, Robert" Publication Year Range Last 50 years
49 results on '"Lash, Robert"'

1. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes

Author

Phillip, Moshe, Achenbach, Peter, Addala, Ananta, Albanese-O’Neill, Anastasia, Battelino, Tadej, Bell, Kirstine J., Besser, Rachel E. J., Bonifacio, Ezio, Colhoun, Helen M., Couper, Jennifer J., Craig, Maria E., Danne, Thomas, de Beaufort, Carine, Dovc, Klemen, Driscoll, Kimberly A., Dutta, Sanjoy, Ebekozien, Osagie, Larsson, Helena Elding, Feiten, Daniel J., Frohnert, Brigitte I., Gabbay, Robert A., Gallagher, Mary P., Greenbaum, Carla J., Griffin, Kurt J., Hagopian, William, Haller, Michael J., Hendrieckx, Christel, Hendriks, Emile, Holt, Richard I. G., Hughes, Lucille, Ismail, Heba M., Jacobsen, Laura M., Johnson, Suzanne B., Kolb, Leslie E., Kordonouri, Olga, Lange, Karin, Lash, Robert W., Lernmark, Åke, Libman, Ingrid, Lundgren, Markus, Maahs, David M., Marcovecchio, M. Loredana, Mathieu, Chantal, Miller, Kellee M., O’Donnell, Holly K., Oron, Tal, Patil, Shivajirao P., Pop-Busui, Rodica, Rewers, Marian J., Rich, Stephen S., Schatz, Desmond A., Schulman-Rosenbaum, Rifka, Simmons, Kimber M., Sims, Emily K., Skyler, Jay S., Smith, Laura B., Speake, Cate, Steck, Andrea K., Thomas, Nicholas P. B., Tonyushkina, Ksenia N., Veijola, Riitta, Wentworth, John M., Wherrett, Diane K., Wood, Jamie R., Ziegler, Anette-Gabriele, and DiMeglio, Linda A.

Published
2024
Full Text
View/download PDF

2. Correction to: Consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes

Author

Phillip, Moshe, Achenbach, Peter, Addala, Ananta, Albanese‑O’Neill, Anastasia, Battelino, Tadej, Bell, Kirstine J., Besser, Rachel E. J., Bonifacio, Ezio, Colhoun, Helen M., Couper, Jennifer J., Craig, Maria E., Danne, Thomas, de Beaufort, Carine, Dovc, Klemen, Driscoll, Kimberly A., Dutta, Sanjoy, Ebekozien, Osagie, Larsson, Helena Elding, Feiten, Daniel J., Frohnert, Brigitte I., Gabbay, Robert A., Gallagher, Mary P., Greenbaum, Carla J., Griffin, Kurt J., Hagopian, William, Haller, Michael J., Hendrieckx, Christel, Hendriks, Emile, Holt, Richard I. G., Hughes, Lucille, Ismail, Heba M., Jacobsen, Laura M., Johnson, Suzanne B., Kolb, Leslie E., Kordonouri, Olga, Lange, Karin, Lash, Robert W., Lernmark, Åke, Libman, Ingrid, Lundgren, Markus, Maahs, David M., Marcovecchio, M. Loredana, Mathieu, Chantal, Miller, Kellee M., O’Donnell, Holly K., Oron, Tal, Patil, Shivajirao P., Pop‑Busui, Rodica, Rewers, Marian J., Rich, Stephen S., Schatz, Desmond A., Schulman‑Rosenbaum, Rifka, Simmons, Kimber M., Sims, Emily K., Skyler, Jay S., Smith, Laura B., Speake, Cate, Steck, Andrea K., Thomas, Nicholas P. B., Tonyushkina, Ksenia N., Veijola, Riitta, Wentworth, John M., Wherrett, Diane K., Wood, Jamie R., Ziegler, Anette‑Gabriele, and DiMeglio, Linda A.

Published
2024
Full Text
View/download PDF

3. Navigating Complexities: Vitamin D, Skin Pigmentation, and Race.

Author

Ospina, Naykky Singh, Diaz-Thomas, Alicia, McDonnell, Marie E, Demay, Marie B, Pittas, Anastassios G, York, Elizabeth, Corrigan, Maureen D, Lash, Robert W, Brito, Juan P, Murad, M Hassan, and McCartney, Christopher R

Subjects
RACE, VITAMIN D, CALCIUM channels, CALCIUM metabolism, CLINICAL trials, VITAMIN D deficiency
Abstract

Vitamin D plays a critical role in many physiological functions, including calcium metabolism and musculoskeletal health. This commentary aims to explore the intricate relationships among skin complexion, race, and 25-hydroxyvitamin D (25[OH]D) levels, focusing on challenges the Endocrine Society encountered during clinical practice guideline development. Given that increased melanin content reduces 25(OH)D production in the skin in response to UV light, the guideline development panel addressed the potential role for 25(OH)D screening in individuals with dark skin complexion. The panel discovered that no randomized clinical trials have directly assessed vitamin D related patient-important outcomes based on participants' skin pigmentation, although race and ethnicity often served as presumed proxies for skin pigmentation in the literature. In their deliberations, guideline panel members and selected Endocrine Society leaders underscored the critical need to distinguish between skin pigmentation as a biological variable and race and ethnicity as socially determined constructs. This differentiation is vital to maximize scientific rigor and, thus, the validity of resulting recommendations. Lessons learned from the guideline development process emphasize the necessity of clarity when incorporating race and ethnicity into clinical guidelines. Such clarity is an essential step toward improving health outcomes and ensuring equitable healthcare practices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication.

Author

McCartney, Christopher R, McDonnell, Marie E, Corrigan, Maureen D, and Lash, Robert W

Subjects
VITAMIN D, DIETARY supplements, CLINICAL trials, HUMILITY, VITAMIN D deficiency
Abstract

A long-held precept is that vitamin D supplementation primarily, if not exclusively, benefits individuals with low circulating 25-hydroxyvitamin D (25[OH]D) concentrations at baseline. However, the most appropriate 25(OH)D threshold to distinguish unacceptably low vs reliably adequate concentrations remains controversial. Such threshold proposals have largely been based on observational studies, which provide less robust evidence compared to randomized clinical trials (RCTs). Since the Endocrine Society's first vitamin D–related guideline was published in 2011, several large vitamin D–related RCTs have been published, and a newly commissioned guideline development panel (GDP) prioritized 4 clinical questions related to the benefits and harms of vitamin D supplementation in generally healthy individuals with 25(OH)D levels below a threshold. The GDP determined that available clinical trial evidence does not permit the establishment of 25(OH)D thresholds that specifically predict meaningful benefit with vitamin D supplementation. The panel noted important limitations in the available evidence, and the panel's overall certainty in the available evidence was very low. Nonetheless, based on the GDP's analyses and judgments, the Endocrine Society no longer endorses its previously proposed definition of vitamin D "sufficiency" (ie, at least 30 ng/mL [75 nmol/L]) or its previously proposed definition of vitamin D "insufficiency" (ie, greater than 20 ng/mL [50 nmol/L] but lower than 30 ng/mL [75 nmol/L]). The Endocrine Society's rationale for such is the subject of this Guideline Communication. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Navigating Complexities: Vitamin D, Skin Pigmentation, and Race

Author

Singh Ospina, Naykky, Diaz-Thomas, Alicia, McDonnell, Marie E, Demay, Marie B, Pittas, Anastassios G, York, Elizabeth, Corrigan, Maureen D, Lash, Robert W, Brito, Juan P, Murad, M Hassan, and McCartney, Christopher R

Abstract

Vitamin D plays a critical role in many physiological functions, including calcium metabolism and musculoskeletal health. This commentary aims to explore the intricate relationships among skin complexion, race, and 25-hydroxyvitamin D (25[OH]D) levels, focusing on challenges the Endocrine Society encountered during clinical practice guideline development. Given that increased melanin content reduces 25(OH)D production in the skin in response to UV light, the guideline development panel addressed the potential role for 25(OH)D screening in individuals with dark skin complexion. The panel discovered that no randomized clinical trials have directly assessed vitamin D related patient-important outcomes based on participants' skin pigmentation, although race and ethnicity often served as presumed proxies for skin pigmentation in the literature. In their deliberations, guideline panel members and selected Endocrine Society leaders underscored the critical need to distinguish between skin pigmentation as a biological variable and race and ethnicity as socially determined constructs. This differentiation is vital to maximize scientific rigor and, thus, the validity of resulting recommendations. Lessons learned from the guideline development process emphasize the necessity of clarity when incorporating race and ethnicity into clinical guidelines. Such clarity is an essential step toward improving health outcomes and ensuring equitable healthcare practices.

Published
2024
Full Text
View/download PDF

8. CLCN2 chloride channel mutations in familial hyperaldosteronism type II

Author

Scholl, Ute I., Stölting, Gabriel, Schewe, Julia, Thiel, Anne, Tan, Hua, Nelson-Williams, Carol, Vichot, Alfred A., Jin, Sheng Chih, Loring, Erin, Untiet, Verena, Yoo, Taekyeong, Choi, Jungmin, Xu, Shengxin, Wu, Aihua, Kirchner, Marieluise, Mertins, Philipp, Rump, Lars C., Onder, Ali Mirza, Gamble, Cory, McKenney, Daniel, Lash, Robert W., Jones, Deborah P., Chune, Gary, Gagliardi, Priscila, Choi, Murim, Gordon, Richard, Stowasser, Michael, Fahlke, Christoph, and Lifton, Richard P.

Published
2018
Full Text
View/download PDF

14. Enhancing the Trustworthiness of the Endocrine Society’s Clinical Practice Guidelines

Author

McCartney, Christopher R, primary, Corrigan, Maureen D, additional, Drake, Matthew T, additional, El-Hajj Fuleihan, Ghada, additional, Korytkowski, Mary T, additional, Lash, Robert W, additional, Lieb, David C, additional, McCall, Anthony L, additional, Muniyappa, Ranganath, additional, Piggott, Thomas, additional, Santesso, Nancy, additional, Schünemann, Holger J, additional, Wiercioch, Wojtek, additional, McDonnell, Marie E, additional, and Murad, M Hassan, additional

Published
2022
Full Text
View/download PDF

16. Weight Can’t Wait: A Guide to Discussing Obesity and Organizing Treatment in the Primary Care Setting

Author

Gallagher, Christine, primary, Corl, Amelia, additional, Dietz, William H., additional, Schoof, Bellinda, additional, Hester, Christina, additional, Peterson, Eric D, additional, Gables, Lisa, additional, Lentz, Michele, additional, Agarwal, Monica, additional, Crump, Margaret, additional, Padden, Diane, additional, Kushner, Robert, additional, Cody Stanford, Fatima, additional, Casanova, Danielle, additional, Ciemins, Elizabeth, additional, Scott, John, additional, Northup, Joe, additional, Lash, Robert, additional, Dyer, Meredith, additional, Nadglowski, Joe, additional, Nece, Patty, additional, Kyle, Ted, additional, Primack, Craig, additional, Horn, Deborah, additional, Morton, Kathleen, additional, Winston, Ginger, additional, Kahan, Scott, additional, Ryan, Donna, additional, Comuzzie, Tony, additional, and Butsch, Scott, additional

Published
2021
Full Text
View/download PDF

17. Missed opportunities for type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus

Author

Kim, Catherine, Tabaei, Bahman P., Burke, Ray, McEwen, Laura N., Lash, Robert W., Johnson, Susan L., Schwartz, Kendra L., Bernstein, Steven J., and Herman, William H.

Subjects
Type 2 diabetes -- Diagnosis, Medical screening, Government, Health care industry
Abstract

Objectives. We sought to determine rates and factors associated with screening for type 2 diabetes mellitus (DM) in women with a history of gestational diabetes mellitus. Methods. We retrospectively studied women with diagnosed gestational diabetes mellitus who delivered at a university-affiliated hospital (n=570). Data sources included medical and administrative record review. Main outcome measures were the frequency of any type of glucose testing at least 6 weeks after delivery and the frequency of recommended glucose testing. We assessed demographic data, past medical history, and prenatal and postpartum care characteristics. Results, Rates of glucose testing after delivery were low. Any type of glucose testing was performed at least once after 38% of deliveries, and recommended glucose testing was performed at least once after 23% of deliveries. Among women with at least 1 visit to the health care system after delivery (n=447), 42% received any type of glucose test at least once, and 35% received a recommended glucose test at least once. Factors associated with testing were being married, having a visit with an endocrinologist after delivery, and having more visits after delivery. Conclusions. These findings suggest that most women with gestational diabetes mellitus are not screened for type 2 DM after delivery. Opportunities for DM prevention and early treatment are being missed. doi: 10.2105/AJPH.2005.065722

Published
2006

22. Monkeypox outbreak—Nine states, May 2022

Author

Minhaj, Faisal S., Ogale, Yasmin P., Whitehill, Florence, Schultz, Jordan, Foote, Mary, Davidson, Whitni, Hughes, Christine M., Wilkins, Kimberly, Bachmann, Laura, Chatelain, Ryan, Donnelly, Marisa A. P., Mendoza, Rafael, Downes, Barbara L., Roskosky, Mellisa, Barnes, Meghan, Gallagher, Glen R., Basgoz, Nesli, Ruiz, Victoria, Kyaw, Nang Thu Thu, Feldpausch, Amanda, Valderrama, Amy, Alvarado‐Ramy, Francisco, Dowell, Chad H., Chow, Catherine C., Li, Yu, Quilter, Laura, Brooks, John, Daskalakis, Demetre C., McClung, R. Paul, Petersen, Brett W., Damon, Inger, Hutson, Christina, McQuiston, Jennifer, Rao, Agam K., Belay, Ermias, McCollum, Andrea M., Angelo, Kristina, Arduino, Matt, Arthur, Ray, Baird, Nicolle, Batross, Jonathan, Beeson, Amy, Bhingarde, Jui, Bowen, Michael, Brown, Clive, Brown, Catherine M., Burakoff, Alexis, Charniga, Kelly, Chen, Tai‐Ho, Chen, Sherry, Clay, Patrick, Cope, James, Cope, Jennifer, Dankwa, Michelle Addo, Delaney, Lisa, De Perio, Marie, Decenteceo, Michelle, Delea, Kristin, Doty, Jeffrey B., Duchin, Jeffrey, Dunlap, Joseph, Fagan, Ryan, Furness, Bryce, Gearhart, Shannon, Gigante, Crystal, Gilliland, Aubrey, Gosdin, Lucas, Griffin, Isabel, Groccia, Amanda, Guagliardo, Sarah, Hercules, Yonette, Jackson, Kelly, Jarquin, Paulino, Kachur, Rachel, Kallen, Alexander, Kao, Raymond, Kelly, Aubree, Khan, Mohammed, Khan, Theodora, Kofman, Aaron, Kornylo, Krista, Kuhar, David, LaFlam, Michael, Lash, Robert, Lashombe, Andrew, Lowe, David, MacGurn, Amanda, Masters, Nina, McCaffrey, Keegan, Mink, Jenna L., Monroe, Benjamin, Morgan, Clint N., Nakazawa, Yoshinori, Nash, Julie, Navarra, Terese, Newton, Donovan, Osinubi, Modupe, Osorio, Valentina, Pearson, Christine, Petras, Julia, Philpott, David, Pickrel, Amy, Potvin, Brandon, Priyamvada, Lalita, Rey, Araceli, Ricketts, Erin, Rodriguez, Sergio, Rushmore, Julie, Satheshkumar, Panayampalli S., Segaloff, Hannah, Sekkarie, Ahlia, Sharma, Artee, Sims, Emily, Smith, Dallas, Smith, Teresa, Smith, Todd, Solanky, Dipesh, Spiknall, Ian, Stanek, Danielle R., Stenger, Mark, Strona, Frank, Tardivel, Kara, Tyagi, Eishita, Wortley, Pascale, Valencia, Diana, Waltenburg, Michelle, Whitehouse, Erin, and Wong, Marcia

Published
2022
Full Text
View/download PDF

26. CLCN2chloride channel mutations in familial hyperaldosteronism type II

Author

Scholl, Ute, Stölting, Gabriel, Schewe, Julia, Thiel, Anne, Tan, Hua, Nelson-Williams, Carol, Vichot, Alfred, Jin, Sheng, Loring, Erin, Untiet, Verena, Yoo, Taekyeong, Choi, Jungmin, Xu, Shengxin, Wu, Aihua, Kirchner, Marieluise, Mertins, Philipp, Rump, Lars, Onder, Ali, Gamble, Cory, McKenney, Daniel, Lash, Robert, Jones, Deborah, Chune, Gary, Gagliardi, Priscila, Choi, Murim, Gordon, Richard, Stowasser, Michael, Fahlke, Christoph, and Lifton, Richard

Abstract

Primary aldosteronism, a common cause of severe hypertension1 , features constitutive production of the adrenal steroid aldosterone. We analyzed a multiplex family with familial hyperaldosteronism type II (FH-II)2 and 80 additional probands with unsolved early-onset primary aldosteronism. Eight probands had novel heterozygous variants in CLCN2, including two de novo mutations and four independent occurrences of a mutation encoding an identical p.Arg172Gln substitution; all relatives with early-onset primary aldosteronism carried the CLCN2variant found in the proband. CLCN2encodes a voltage-gated chloride channel expressed in adrenal glomerulosa that opens at hyperpolarized membrane potentials. Channel opening depolarizes glomerulosa cells and induces expression of aldosterone synthase, the rate-limiting enzyme for aldosterone biosynthesis. Mutant channels show gain of function, with higher open probabilities at the glomerulosa resting potential. These findings for the first time demonstrate a role of anion channels in glomerulosa membrane potential determination, aldosterone production and hypertension. They establish the cause of a substantial fraction of early-onset primary aldosteronism. Whole-exome sequencing identifies mutations in CLCN2in individuals with familial hyperaldosteronism type II or early-onset primary aldosteronism. These gain-of-function mutations cause chloride channel opening and glomerulosa cell depolarization, showing a role for anion channels in aldosterone production.

Published
2018
Full Text
View/download PDF

29. Case Report

Author

Williams, Jennifer, primary, Pomeroy, Nathan E., additional, Pop-Busui, Rodica, additional, Lash, Robert, additional, Douyon, Liselle, additional, Chames, Mark, additional, and Wyckoff, Jennifer, additional

Published
2009
Full Text
View/download PDF

38. Diagnosis and Management of Gestational Diabetes Mellitus.

Author

SERLIN, DAVID C. and LASH, ROBERT W.

Subjects
DIAGNOSIS of diabetes, GESTATIONAL diabetes, PREGNANCY complications, DIABETES complications, BLOOD sugar monitoring, TYPE 2 diabetes, FETAL monitoring, AMNIOTIC liquid examination
Abstract

Gestational diabetes occurs in 5 to 9 percent of pregnancies in the United States and is growing in prevalence. It is a controversial entity, with conflicting guidelines and treatment protocols. Recent studies show that diagnosis and management of this disorder have beneficial effects on maternal and neonatal outcomes, including reduced rates of shoulder dystocia, fractures, nerve palsies, and neonatal hypoglycemia. Diagnosis is made using a sequential model of universal screening with a 50-g one-hour glucose challenge test, followed by a diagnostic 100-g three-hour oral glucose tolerance test for women with a positive screening test. Treatment consists of glucose monitoring, dietary modification, exercise, and, when necessary, pharmacotherapy to maintain euglycemia. Insulin therapy is the mainstay of treatment, although glyburide and metformin may become more widely used. In women receiving pharmacotherapy, antenatal testing with nonstress tests and amniotic fluid indices beginning in the third trimester is generally used to monitor fetal well-being. The method and timing of delivery are controversial. Women with gestational diabetes are at high risk of subsequent development of type 2 diabetes. Lifestyle modification should therefore be encouraged, along with regular screening for diabetes. [ABSTRACT FROM AUTHOR]

Published
2009

49. Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276-1298.

Author

Phillip M, Achenbach P, Addala A, Albanese-O'Neill A, Battelino T, Bell KJ, Besser REJ, Bonifacio E, Colhoun HM, Couper JJ, Craig ME, Danne T, Beaufort C, Dovc K, Driscoll KA, Dutta S, Ebekozien O, Larsson HE, Feiten DJ, Frohnert BI, Gabbay RA, Gallagher MP, Greenbaum CJ, Griffin KJ, Hagopian W, Haller MJ, Hendrieckx C, Hendriks E, Holt RIG, Hughes L, Ismail HM, Jacobsen LM, Johnson SB, Kolb LE, Kordonouri O, Lange K, Lash RW, Lernmark Å, Libman I, Lundgren M, Maahs DM, Marcovecchio ML, Mathieu C, Miller KM, O'Donnell HK, Oron T, Patil SP, Pop-Busui R, Rewers MJ, Rich SS, Schatz DA, Schulman-Rosenbaum R, Simmons KM, Sims EK, Skyler JS, Smith LB, Speake C, Steck AK, Thomas NPB, Tonyushkina KN, Veijola R, Wentworth JM, Wherrett DK, Wood JR, Ziegler AG, and DiMeglio LA

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results